Therapeutic Area Director
+9 year(s) experience
He stays abreast of market developments, generating and curating data sources, and distilling these into reports that enable clients to gain a competitive edge.
Since joining Pharma Intelligence in 2010, Daniel has tracked and forecast all the leading neurology, psychiatry, and pain drug markets. He is particularly interested in the shifting landscape of the multiple sclerosis market well as the implications of trial failures – alongside the successes in Alzheimer's disease R&D.
He has helped expand research and insight on rare diseases , including established orphan drug markets as well as as emerging opportunities. He also attends international medical conferences and enjoys collaborating with colleagues at Scrip.
Daniel has a First Class degree in Natural Sciences from the University of Bath.
Biomedtracker, Datamonitor Healthcare
By Daniel Chancellor 06 Aug 2019
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Datamonitor Healthcare, Pharmaprojects, Biomedtracker
By Daniel Chancellor 03 Jul 2019
In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.
By Daniel Chancellor 11 Jun 2019
In April, immuno-oncology (IO) celebrated its ninth birthday, following the approval of Provenge, the first drug that harnesses the body’s immune system to fight cancer, in April 2010. Since this landmark event, it has been a tremendous decade for the field, with IO becoming part of the standard-of-care in a range of treatment settings and the Nobel Prize being awarded for the discovery of immune checkpoint inhibition. It is the checkpoint inhibitor drug classes that are leading the IO revolution and will act as a foundation for the next decade of oncology research. This article reviews the childhood years of IO and predicts what the future may hold as it reaches double digits and matures through adolescence.
By Daniel Chancellor 22 Jan 2016
Alkermes has announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461 (buprenorphine/samidorphan), yet is emboldened by an efficacy signal
By Daniel Chancellor 03 Aug 2015
Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.
Topic Parkinsons disease
By Daniel Chancellor 23 Jul 2015
Biogen and Eli Lilly both presented much-anticipated data at the 2015 Alzheimer’s Association International Conference (AAIC) in Washington DC for their respective anti-beta amyloid
By Daniel Chancellor 03 Jun 2015
With ASCO over for another year we’ve put together an overview of key highlights from this year’s conference. Our NEW white paper allows you to read through the results and implications of these key abstracts, chosen by our expert analysts, allowing you and your business to evolve with the oncology market.
By Daniel Chancellor 17 Sep 2014
The US Food and Drug Administration (FDA) has approved Orexigen’s Contrave (naltrexone + bupropion) for the treatment of obesity, while panelists on an FDA advisory committee voted in favor
Topic Drug approval
10 Sep 2019
03 Jun 2019
30 May 2019
15 Apr 2019
24 Oct 2016
26 Jan 2016
13 Oct 2015